 SEATTLE--BUSINESS WIRE--Omeros Corporation Nasdaq: OMER today announced that Nadia Dac has joined Omeros as its Chief Commercial Officer. In this role, Ms. Dac will be responsible for all commercial operations at Omeros, including overseeing preparations for the commercial launch of narsoplimab, the companys mannan-binding lectin-associated serine protease-2 MASP-2 inhibitor. A Biologics License Application for narsoplimab in the treatment of hematopoietic stem cell transplant-associated 